Largest healthcare initiative of its kind in Canada launched to conquer cancer in our lifetime TORONTO, April 12, 2012 /PRNewswire/ - Amidst the skirl of the pipes and a

TORONTO, April 3, 2012 /PRNewswire/ -- Mobile Integrated Systems, Inc (OTCBB:LOTID), operating through its wholly-owned subsidiary Mobilotto Systems, Inc.

Low oxygen levels in tumors can be used to predict cancer recurrence in men with intermediate-risk prostate cancer even before they receive radiation therapy.

TORONTO, Feb.

For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride ("Avodart") delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network (UHN).